• 1
    Benkerrou M, Durandy A, Fischer A. Therapy for transplant-related lymphoproliferative diseases. Hematol Oncol Clin North Am 1993; 7: 467475.
  • 2
    Bhatia S, Ramsay NK, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 36333639.
  • 3
    Armitage JM, Kormos RL, Stuart RS et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: Ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10: 877886.
  • 4
    Shapiro RS, McClain K, Frizzera G et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 12341243.
  • 5
    Zutter MM, Martin PJ, Sale GE et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520529.
  • 6
    Patel H, Vogl DT, Aqui NA et al. Posttransplant lymphoproliferative disorder in adult liver transplant recipients: A report of seventeen cases. Leuk Lymphoma 2007; 48: 885891.
  • 7
    Tsai DE, Hardy CL, Tomaszewski JE et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 10761088.
  • 8
    McDiarmid SV, Jordan S, Kim GS et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 16041611.
  • 9
    Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated posttransplantation lymphoproliferative disease. Br J Haematol 1995; 89: 98103.
  • 10
    Tsai DE, Nearey M, Hardy CL et al. Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients. Am J Transplant 2002; 2: 946954.
  • 11
    Green M, Webber S. EBV viral load monitoring: Unanswered questions. Am J Transplant 2002; 2: 894895.
  • 12
    Lee TC, Savoldo B, Rooney CM et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005; 5: 22222228.
  • 13
    Ahya VN, Douglas LP, Readis C et al. Association between elevated whole blood EBER EBV PCR and reduced incidence of acute lung allograft rejection. J Heart Lung Transplant 2007; 26: 839844.
  • 14
    Oertel SH, Vershuuren E, Reinke P et al. Effect of anti-CD20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005; 5: 29012906.
  • 15
    Choquet S, Leblond V, Herbrecht R et al. Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006; 107: 30533057.
  • 16
    McKelvey EM, Gottlieb JA, Wilson HE et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 14841493.
  • 17
    Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 15491555.
  • 18
    Wagner HJ, Wessel M, Jabs W et al. Patients at risk for development of posttransplant lymphoproliferative disorder: Plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr virla load by using real time quantitative polymerase chain reaction. Transplantation 2001; 72: 10121019.
  • 19
    Bakker NA, Verschuuren EA, Erasmus ME et al. Epstein-Barr virus-DNA load monitoring late after lung transplantation: A surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Transplantation 2007; 83: 433438.
  • 20
    Oertel SH, Trappe RU, Zeidler K et al. Epstein-Barr virus load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Ann Hematol 2006; 85: 478484.
  • 21
    Jain AB, Marcos A, Pokharna R et al. Rituximab for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: Long-term experience from a single center. Transplantation 2005; 80: 16921698.
  • 22
    Mamzer-Bruneel MF, Lome C, Morelon E et al. Durable remission after aggressive chemotherapy for very late post- kidney transplant lymphoproliferation: A report of 16 cases observed in a single center. J Clin Oncol 2000; 18: 36223632.
  • 23
    Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995; 86: 33333340.
  • 24
    Elstrom RL, Readis C, Aqui NA et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6: 569576.
  • 25
    Green M, Caccuarelli T, Mazareigos G. Serial measurements of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients for posttransplant lymphoproliferative disorder. Transplant 1998; 66: 16411644.
  • 26
    Green M, Reyes J, Webber S, Michaels MG, Rowe DT. The role of viral load in the diagnosis, management and possible prevention of Epstein-Barr virus associated posttransplant lymphoproliferative disease following solid organ transplantation. Current Opion Transplant 1999; 4: 292296.
  • 27
    Wada K, Kubota N, Ito Y et al. Simultaneous quantification of Epstein-Barr virus, cytomegalovirus, and human herpes 6 DNA in samples from transplant recipients by ultiplex real-time PCR assay. J Clin Microbiol 2007; 45: 14261432.